Cargando…

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia

BACKGROUND: Dyslipidemia represents significant health care concerns in patients taking antiretroviral therapy due to their association with cardiovascular disease risk. There is limited data regarding the effects of boosted atazanavir (ATV/r) treatment in the lipid profiles of Ethiopian HIV patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Muche Belete, Abebe, Seifu, Daniel, Menon, Menakath, Amogne, Wondwossen, Shewa, Aster, Adela Tefera, Alemu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903961/
https://www.ncbi.nlm.nih.gov/pubmed/33642881
http://dx.doi.org/10.2147/HIV.S296170
_version_ 1783654836629143552
author Muche Belete, Abebe
Seifu, Daniel
Menon, Menakath
Amogne, Wondwossen
Shewa, Aster
Adela Tefera, Alemu
author_facet Muche Belete, Abebe
Seifu, Daniel
Menon, Menakath
Amogne, Wondwossen
Shewa, Aster
Adela Tefera, Alemu
author_sort Muche Belete, Abebe
collection PubMed
description BACKGROUND: Dyslipidemia represents significant health care concerns in patients taking antiretroviral therapy due to their association with cardiovascular disease risk. There is limited data regarding the effects of boosted atazanavir (ATV/r) treatment in the lipid profiles of Ethiopian HIV patients. Thus, this study compares the mean values of lipid profile differences of HIV patients on ATV/r-based regimen compared to efavirenz (EFV)-based regimen, while the background is Tenofovir Disoproxil Fumarate/lamivudine. MATERIALS AND METHODS: A comparative hospital-based cross-sectional study was conducted among adult HIV-infected patients at Zewditu Memorial Hospital, Addis Ababa, Ethiopia, from July–September 2017. An equal number of EFV and ATV/r-treated patients (n=90 each) receiving for 1-year and over were included in the study. Serum total cholesterol (TC), triglyceride (TG), gigh-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were measured. Data comparison used chi-square test, Student’s t-test and Mann–Whitney U-test. Multivariate logistic regression analysis and p-value<0.05 were used to identify associated factors of serum lipid profiles. RESULTS: In the present study, the ATV/r-treated group results were significantly higher in the median values of TG [207 (56–1094) vs 145 (42–768) mg/dL; p=0.001] and the mean value of TG/HDL-c (6.6 vs 4.4; p=0.001) as compared to the EFV-treated group. The EFV-treated group showed significantly higher in the mean value of HDL-c (44.7 vs 38.7 mg/dL; p=0.001) as compared to the ATV/r-treated group. Body mass index was associate with LDL and HDL. CD4 was associated with TC. Current antiretroviral therapy was associated with TG. Duration of HIV since first diagnosis and duration of ART were associated with HDL. CONCLUSION: ATV/r is associated with elevated in TG and TG/HDL-C, but low HDL as compared to EFV. Differences in LDL or HDL that were found were of unclear clinical significance. The long-term significance is unknown.
format Online
Article
Text
id pubmed-7903961
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79039612021-02-25 Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia Muche Belete, Abebe Seifu, Daniel Menon, Menakath Amogne, Wondwossen Shewa, Aster Adela Tefera, Alemu HIV AIDS (Auckl) Original Research BACKGROUND: Dyslipidemia represents significant health care concerns in patients taking antiretroviral therapy due to their association with cardiovascular disease risk. There is limited data regarding the effects of boosted atazanavir (ATV/r) treatment in the lipid profiles of Ethiopian HIV patients. Thus, this study compares the mean values of lipid profile differences of HIV patients on ATV/r-based regimen compared to efavirenz (EFV)-based regimen, while the background is Tenofovir Disoproxil Fumarate/lamivudine. MATERIALS AND METHODS: A comparative hospital-based cross-sectional study was conducted among adult HIV-infected patients at Zewditu Memorial Hospital, Addis Ababa, Ethiopia, from July–September 2017. An equal number of EFV and ATV/r-treated patients (n=90 each) receiving for 1-year and over were included in the study. Serum total cholesterol (TC), triglyceride (TG), gigh-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were measured. Data comparison used chi-square test, Student’s t-test and Mann–Whitney U-test. Multivariate logistic regression analysis and p-value<0.05 were used to identify associated factors of serum lipid profiles. RESULTS: In the present study, the ATV/r-treated group results were significantly higher in the median values of TG [207 (56–1094) vs 145 (42–768) mg/dL; p=0.001] and the mean value of TG/HDL-c (6.6 vs 4.4; p=0.001) as compared to the EFV-treated group. The EFV-treated group showed significantly higher in the mean value of HDL-c (44.7 vs 38.7 mg/dL; p=0.001) as compared to the ATV/r-treated group. Body mass index was associate with LDL and HDL. CD4 was associated with TC. Current antiretroviral therapy was associated with TG. Duration of HIV since first diagnosis and duration of ART were associated with HDL. CONCLUSION: ATV/r is associated with elevated in TG and TG/HDL-C, but low HDL as compared to EFV. Differences in LDL or HDL that were found were of unclear clinical significance. The long-term significance is unknown. Dove 2021-02-19 /pmc/articles/PMC7903961/ /pubmed/33642881 http://dx.doi.org/10.2147/HIV.S296170 Text en © 2021 Muche Belete et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Muche Belete, Abebe
Seifu, Daniel
Menon, Menakath
Amogne, Wondwossen
Shewa, Aster
Adela Tefera, Alemu
Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
title Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
title_full Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
title_fullStr Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
title_full_unstemmed Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
title_short Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
title_sort serum lipid profiles of patients taking efavirenz-based antiretroviral regimen compared to ritonavir-boosted atazanavir with an optimized background at zewditu memorial hospital, addis ababa, ethiopia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903961/
https://www.ncbi.nlm.nih.gov/pubmed/33642881
http://dx.doi.org/10.2147/HIV.S296170
work_keys_str_mv AT muchebeleteabebe serumlipidprofilesofpatientstakingefavirenzbasedantiretroviralregimencomparedtoritonavirboostedatazanavirwithanoptimizedbackgroundatzewditumemorialhospitaladdisababaethiopia
AT seifudaniel serumlipidprofilesofpatientstakingefavirenzbasedantiretroviralregimencomparedtoritonavirboostedatazanavirwithanoptimizedbackgroundatzewditumemorialhospitaladdisababaethiopia
AT menonmenakath serumlipidprofilesofpatientstakingefavirenzbasedantiretroviralregimencomparedtoritonavirboostedatazanavirwithanoptimizedbackgroundatzewditumemorialhospitaladdisababaethiopia
AT amognewondwossen serumlipidprofilesofpatientstakingefavirenzbasedantiretroviralregimencomparedtoritonavirboostedatazanavirwithanoptimizedbackgroundatzewditumemorialhospitaladdisababaethiopia
AT shewaaster serumlipidprofilesofpatientstakingefavirenzbasedantiretroviralregimencomparedtoritonavirboostedatazanavirwithanoptimizedbackgroundatzewditumemorialhospitaladdisababaethiopia
AT adelateferaalemu serumlipidprofilesofpatientstakingefavirenzbasedantiretroviralregimencomparedtoritonavirboostedatazanavirwithanoptimizedbackgroundatzewditumemorialhospitaladdisababaethiopia